高级检索
当前位置: 首页 > 详情页

Chinese Herbal Medicine for Obesity: A Randomized, Double-Blinded, Multicenter, Prospective Trial

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China [2]China Acad Chinese Med Sci, Hosp Eye, Beijing 100053, Peoples R China [3]Tianjin Med Univ, Metab Dis Hosp, Minist Hlth, Key Lab Hormones & Dev, Tianjin, Peoples R China [4]Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin, Peoples R China [5]Tasly Pharmaceut Co Ltd, Tianjin, Peoples R China [6]Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China [7]China Japan Friendship Hosp, Beijing, Peoples R China [8]Yangfangdian Hosp, Beijing, Peoples R China
出处:
ISSN:

关键词: Overweight Obesity Body Weight Control Chinese Medicine Xin-Ju-Xiao-Gao-Fang Rhubarb Coptis Semen cassia Citrus aurantium Clinical Trial

摘要:
Obesity is a serious medical problem worldwide. As a holistic therapy, traditional Chinese medicine (TCM) may have a potential in obesity management. In this controlled trial, we evaluated the safety and effectiveness of Xin-Ju-Xiao-Gao-Fang (XJXGF), a TCM herbal formulation, in 140 obese subjects over a 24-week period. The XJXGF formula mainly consists of rhubarb, coptis, semen cassia, and citrus aurantium. Subjects with body mass index (BMI) 28-40 kg/m(2) were recruited at 5 centers in China. We assessed the changes in subjects' body weight, its related parameters, and the reduction of insulin resistance (IR) after administration of XJXGF formula or low-dose XJXGF (10% of the XJXGF formula, as control). After 24-week treatment, among participants in the XJXGF formula group and low-dose XJXGF group, the mean +/- SE changes in the body weight were -3.58 +/- 0.48 and -1.91 +/- 0.38 kg, respectively (p < 0.01). The changes in the IR-index of two groups were -2.65 +/- 1.04 and -1.58 +/- 1.3, respectively (p < 0.05). There were no serious adverse events reported during the 24-week trial. Participants reported 7 minor adverse events, 4 in the XJXGF formula group and 3 in the low-dose XJXGF group (p = 0.578). Future studies are needed to investigate the clinical utility of this TCM formulation in the treatment of obese subjects.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 4 区 医学
小类 | 3 区 全科医学与补充医学 3 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 全科医学与补充医学 2 区 医学:内科
JCR分区:
出版当年[2012]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2012版] 出版当年五年平均[2008-2012] 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China
通讯作者:
通讯机构: [1]China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China [*1]China Acad Chinese Med Sci, Guanganmen Hosp, 5 Beixiange St, Beijing 100053, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)